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Abstract
Despite large public investments in genome-wide association studies of common human diseases,
so far, few gene discoveries have led to applications for clinical medicine or public health.
Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be
quicker to yield clinical applications. Certain methodological concerns, such as selection bias and
confounding, may be mitigated when genome-wide association studies are conducted within
clinical trials, in which randomization of exposure, prospective evaluation of outcome and careful
definition of phenotype are incorporated by design.
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Introduction
Since 2007, genome-wide association studies (GWASs) have
emerged as a powerful tool to identify disease-related genes
for many common human disorders and other phenotypes
[1]. The National Human Genome Research Institute (NHGRI)
[2] and the Centers for Disease Control and Prevention
(CDC) both maintain online resources for tracking published
GWASs. Data from the CDC HuGE Navigator [3,4], an
online, curated and searchable knowledge base in human
genome epidemiology, show that the number of published
GWASs grew from only a handful before 2007 to more than
300 as of mid-March 2009.
GWASs are characterized by the need for very large study
populations and replication samples because the expected
effect sizes are small and the expected number of false
positive findings is large [5,6]. Thus, although the cost of
genotyping has decreased rapidly (and is expected to
decrease further), GWASs remain a costly approach.
Recently, the National Cancer Institute announced $96
million in grants over 4 years to support post-GWAS
cancer studies to replicate and understand the biological
basis of gene discoveries [7]. These investments are in
addition to the approximately $3 billion spent on the
Human Genome Project [8], which was justified to the
public largely on the basis of its potential to identify
genetic risk factors leading to prevention and treatment of
common diseases.
The conventional GWAS approach is a hypothesis-free, sys-
tematic search of tagging single nucleotide polymorphisms
(SNPs) across the genome to identify novel associations with
common diseases. Although many such associations have
been found and replicated, their effect sizes are modest at
best (odds ratios mostly between 1.0 and 1.5) and they
generally lack sufficient clinical sensitivity, specificity and
predictive value to serve as risk or screening markers [9].
Furthermore, in the absence of contextual information -
such as potential functional implications at the molecular
level, influence on physiologic processes or potential
environmental interactions - these associations provide only
a starting point for further research [10].
GWASs in pharmacogenomics: opportunities
Pharmacogenomics has often been represented as the
leading edge in translating human genomic research for
clinical practice, creating the basis for personalized
medicine [11,12]. It examines inter-individual variation in
drug effects as a function of genetic variation by integrating
epidemiological, genetic, pharmacological and clinical
measurements. Results of the 12 pharmacogenomics
GWASs published so far are summarized in a recent review
by Crowley et al. [13], as well as in the NHGRI GWAS
catalog [2]. Six GWASs evaluated the association of genetic
variation with drug efficacy, five evaluated adverse effects,
and one examined a dose-response relationship (warfarin)
[4]. The GWAS approach has succeeded in discovering new
associations with adverse drug effects, even though the
biological mechanisms may be obscure. An example is the
recent identification of a common variant in the SCLO1B1
gene that markedly increases the risk of statin-induced
myopathy (odds ratio: 4.7-61.1, P = 4.1 × 10-9) [14]. The
investigators estimated that 60% of incident myopathy
could be attributed to the newly identified variant. GWASs
have also found genetic variants associated with individual
responses to drugs, including analgesics and chemo-
therapeutic agents [15,16]. GWASs have been recognized as
an important approach for uncovering polymorphisms
accounting for individual differences in drug efficacy and
drug safety [17].
A vast reservoir of observational studies and randomized
clinical trials (RCTs) - completed, ongoing or planned -
provides a largely untapped resource for pharmacogenomic
studies of drug safety and efficacy. In particular, RCTs allow
for precise measurement of drug exposure and consistent
ascertainment of phenotype; randomization produces un-
biased treatment assignments and helps balance unmeasured
confounding factors [18]. Performing GWASs within clinical
trials, in which more potentially interacting variables can be
identified, measured and controlled, improves efficiency.
Khoury and Wacholder recently stressed that effects
measured in GWASs will be correct only when gene-environ-
ment interactions are taken into account [19]; pharmaco-
genomic studies examine gene-environment interactions by
definition.
GWASs in pharmacogenomics: challenges
GWASs in pharmacogenomics also present challenges. So
far, most such studies have included far fewer participants
(average approximately 200) than the very large sample
sizes typical of GWASs of common diseases [13]. Neverthe-
less, even small pharmacogenomics GWASs have been
successful in identifying robust associations because redu-
cing variability in the definition and ascertainment of
exposure and outcome increases their power to detect
clinically meaningful effects. Nevertheless, larger studies will
be required to detect smaller or less common effects.
The absolute cost of GWASs in pharmacogenomics remains
as high as in other fields, but in the context of drug RCTs and
observational studies for side effects, the marginal cost of
genotyping is small: as Roses recently pointed out [20], the
entire investment in DNA sample collection and genotyping
up to now is only a small fraction of the currently estimated
cost to develop a single drug. At present, investment in
GWASs, pharmacogenomics and clinical trials of drug safety
and efficacy are not coordinated. From 2001 to mid-March
2009, HuGE Navigator identified 2,967 articles on pharma-
cogenomics, of which only 299 (10%) were clinical trials and
12 (0.4%) were GWASs; these 12 articles accounted for just
4% of all GWASs [4] (Figure 1). A coordinated approach to
GWASs in RCTs could lead to more efficient pharmaco-
genomic research. A first step would be to collect appro-
priate biological samples from all clinical trial participants
and obtain their informed consent for future pharmaco-
genomic research studies.
Many drug adverse effects are rare, coming to light only after
a drug becomes available for widespread use [21]. Clinical
trial participants are a key reference population for subse-
quent investigation of adverse effects in case-control
GWASs. In addition, observational studies built on practice-
based settings (such as the health maintenance organization
(HMO) research network [22,23]) can provide clues to
adverse drug effects and differences in effectiveness in ‘real’
world settings, outside the restricted conditions of RCTs.
So far, only two GWASs have been conducted in drug clinical
trials; each of these studies provides relevant insights for
future research. A study of electrocardiographic abnor-
malities during iloperidone treatment of schizophrenia [24]
illustrated the feasibility of performing GWASs in a phase III
clinical trial evaluating the efficacy, safety and tolerability of
a novel drug. A report on statin-related myopathy [14]
demonstrated the efficiency of performing a nested case-
control GWAS within a clinical trial.
Given their efficiency and potential for leading to useful
clinical medicine and public health applications, it seems
surprising that so few GWASs have been done in the field of
pharmacogenomics, especially within clinical trials. The
incentives for conducting such studies deserve closer
evaluation. The US Food and Drug Administration has
encouraged clinical trial sponsors to submit pharmaco-
genomic data, including GWASs, on a voluntary basis [25].
The National Institutes of Health has recently established
funding priorities and requirements for GWASs in govern-
ment-funded clinical trials [26]. In parallel, the prevailing
method of reporting results - typically limited to novel
‘GWAS hits’ or to one candidate gene at a time - should be
revisited. Recently, the investigators in the CATIE trial of
antipsychotic therapy in schizophrenia demonstrated the
feasibility of sharing complete pharmacogenomic study data
and discussed the utility of this approach for the scientific
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community [27]. Comprehensive reporting of GWAS results
in standardized formats will enhance opportunities for
evidence synthesis through meta-analysis [28]. Thus, GWASs
can not only identify novel associations for further study, but
can help counter the selective reporting and pursuit of false
positive findings that may occur when pharmacogenomic
studies are limited to candidate genes [29].
Conclusions
The past few years have seen a flurry of GWAS findings, but
few have found their way to clinical application. Pharmaco-
genomics studies, especially clinical trials, provide a
promising setting for the GWAS approach, which has already
shown success in identifying key genetic determinants of
drug efficacy and adverse effects. Despite the potential for
effective translation of such findings, few GWASs have been
conducted in pharmacogenomics. The incentives for
conducting such studies deserve closer evaluation.
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and HuGE Navigator publication databases were searched by the
following terms: PubMed: “pharmacogenet* OR pharmacogenom*” (PGx).
HuGE Navigator (total publications 40,858): “pharmacogenomics”
(PGxE); “GWAS” (GWAS). Searches performed on 17 March 2009.
Areas are not to scale.
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